Influenza Vaccine Manufacturers’ Panel Discussion: Setting the Stage

Litjen (L.J) Tan
Chief Strategy Officer, IAC
Co-Chair, NAIIS

Setting the Stage

• Things to celebrate (and sustain) from previous flu season
  – Increased in doses administered, by manufacturers’ data potentially 17% increase
  – Improvements resulted from concerted CDC messaging, and unified common messages and voices amplified through the Summit and partners

• Things that remain challenging
  – Dramatic fall off in influenza immunizations past November, acknowledging the difficulty of continuing to emphasize flu in the absence of disease and in the midst of a pandemic (see graphic)
  – Lots of vulnerable and underserved populations continued to be under-immunized
  – Vaccine supply has been stable for many years. How do we work together to ensure that we use all doses to protect as many people as possible?
Patient and Provider Behaviors over the past two Influenza Seasons

Monthly 2020-2021 Claims vs Prior Two Seasons

<table>
<thead>
<tr>
<th>Year</th>
<th>Flu Vaccine Manufactured (M)</th>
<th>Immunizations Administered (M)</th>
<th>Vaccine Un-utilized (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>167</td>
<td>150</td>
<td>17</td>
</tr>
<tr>
<td>2019</td>
<td>176</td>
<td>151</td>
<td>25</td>
</tr>
<tr>
<td>2020</td>
<td>208</td>
<td>177</td>
<td>31</td>
</tr>
</tbody>
</table>

Source: IQVIA National Pharmacy Claims, includes Retail & Medical Order through March 2021

Medical Claims: IQVIA – Sanofi Pasteur Vaccine Datamart through March 2021; CDC Doses Distributed

Setting the Stage

• Things to celebrate (and sustain) from previous flu season
  – Increased in doses administered, by manufacturers’ data potentially 17% increase
  – Improvements resulted from concerted CDC messaging, and unified common messages and voices amplified through the Summit and partners

• Things that remain challenging
  – Dramatic fall off in influenza immunizations past November, acknowledging the difficulty of continuing to emphasize flu in the absence of disease and in the midst of a pandemic
  – Lots of vulnerable and underserved populations continued to be under-immunized
  – Vaccine supply has been stable for many years. How do we work together to ensure that we use all doses to protect as many people as possible?
Estimated Supply for the 2021-2022 Season

- Influenza vaccine supply has not been a challenge for many years.
- Manufacturers estimate that there will be a combined total of >190 million doses available this 2021-2022 influenza season.
  - Compared with ~170 million doses administered last season (the most ever used)